Recruiting

Observational Study

Sponsor:

University of Pennsylvania

Code:

NCT02817997

Conditions

Castleman Disease

Castleman's Disease

Giant Lymph Node Hyperplasia

Angiofollicular Lymph Hyperplasia

Angiofollicular Lymph Node Hyperplasia

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.

Conditions

Castleman Disease

Castleman's Disease

Giant Lymph Node Hyperplasia

Angiofollicular Lymph Hyperplasia

Angiofollicular Lymph Node Hyperplasia

Study ID

NCT02817997

Start date

Oct, 2016

Status verified date

Feb, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Person of any age
  • Have a reference pathology report suggesting "Castleman disease" not limited to cutaneous involvement only that can be uploaded
  • Be able to provide electronic informed consent, as per local regulations
  • Deceased patients may also be enrolled when a reference pathology report suggesting "Castleman disease" can be supplied or when the ART is able to locate and upload such a pathology report.

Exclusion Criteria:

  • Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Common Symptoms [ Time Frame: 5 years ]
  • Common Laboratory Abnormalities [ Time Frame: 5 years ]
  • Treatment [ Time Frame: 5 years ]
  • Survival [ Time Frame: 5 years ]
  • Identify patient subtypes [ Time Frame: 4 years ]
  • Identify clinical outcome measures [ Time Frame: 4 years ]
  • Identify clinical biomarkers [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Joshua Brandstadter, MD, PhD, MSc

267-847-8220joshua.brandstadter@pennmedicine.upenn.edu

Bridget Austin, MSc

2675869977accelerate@uphs.upenn.edu

Locations

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Joshua Brandstadter, MD, PhD, MSc

267-847-8220joshua.brandstadter@pennmedicine.upenn.edu

Bridget Austin, MSc

267-586-9977accelerate@uphs.upenn.edu

Principal Investigator:

Joshua C Brandstadter, MD, PhD, MSc

More Information

Sponsor

University of Pennsylvania

Last update posted

Mar 3, 2026

Last verified

Feb, 2026

Keywords

  • patient registry
  • ACCELERATE study
  • CD
  • MCD
  • iMCD
  • Castleman
  • Castleman's Disease
  • Angiofollicular Lymph Hyperplasia
  • multicentric Castleman's disease
  • multicentric Castleman disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-03-03.